文献速递系统性红斑狼疮

系统性红斑狼疮2021年DORIS缓解定义是否与治疗风湿科医生的判断一致

Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该横断面分析基于西班牙前瞻性多中心SLE研究508例患者,267例(54.4%)符合2021年DORIS缓解标准,277例(55.9%)被医生判定为缓解或血清学活动但临床静止(SACQ)。两种评估总体一致率81.2%(95%CI:79.9,82.9%),Cohen kappa 0.62(0.55-0.69)。不一致主要因医生将部分持续轻度疾病活动患者判为缓解。

要点

  • 508例SLE患者中267例(54.4%)符合2021年DORIS缓解标准。
  • 医生判定缓解或SACQ者277例(55.9%),与DORIS总体一致率81.2%,kappa 0.62。
  • 46例(9.1%)被医生判为缓解/SACQ但不符合DORIS标准,主因cSLEDAI>0(39例)。

核心结论

  • 2021年DORIS缓解在临床实践中是可实现的目标,DORIS定义与医生判断的缓解之间具有实质性一致。
  • 不一致主要由于医生将部分持续轻度疾病活动患者判为缓解。
  • 因此,在SLE管理的达标治疗策略中应使用标准化的DORIS定义来定义目标。

研究设计与样本

  • 对西班牙前瞻性多中心SLE研究数据的横断面分析,应用2021年DORIS标准并评估其与医生临床判断缓解的一致性及不一致原因。
  • 共纳入508例患者,92%为女性,平均年龄(标准差)50.4岁(13.7)。

主要发现

  • 267例(54.4%)符合2021年DORIS缓解标准。
  • 基于医生判断,277例(55.9%)被归类为缓解或血清学活动但临床静止(SACQ)。
  • 两种评估的总体一致率为81.2%(95%CI:79.9,82.9%),Cohen kappa为0.62(0.55-0.69)。
  • 46例(9.1%)被风湿科医生判为缓解/SACQ但不符合2021年DORIS缓解标准。
  • 不一致的主要原因包括39例临床SLE疾病活动指数(cSLEDAI)评分>0、5例医生整体评估(PGA)评分>0.5、另5例泼尼松>5 mg/天。

关键数值与推荐

  • 2021年DORIS缓解标准:267例(54.4%)符合。
  • 医生判定缓解或SACQ:277例(55.9%)。
  • 总体一致率81.2%(95%CI:79.9,82.9%),Cohen kappa 0.62(0.55-0.69)。
  • 不一致原因:cSLEDAI>0者39例,PGA>0.5者5例,泼尼松>5 mg/天者5例。

临床怎么用

  • 作者认为,在SLE管理的达标治疗策略中应使用标准化的DORIS定义来定义目标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess agreement between the 2021 Definition Of Remission In SLE (DORIS) and physician-judged lupus activity. METHODS: A cross-sectional analysis was conducted of data from a Spanish prospective multicentre study of SLE patients. We applied the 2021 DORIS criteria and assessed whether remission status based on this definition agreed with remission as per physician clinical judgement and reasons for disagreement between them. RESULTS: Out of 508 patients [92% women; mean age (s.d.): 50.4 years (13.7)] studied, 267 (54.4%) met the criteria for 2021 DORIS remission. Based on physicians' judgement, 277 (55.9%) patients were classified as in remission or serologically active clinically quiescent (SACQ). The overall rate of agreement between these assessments was 81.2% (95% CI: 79.9, 82.9%) with a Cohen's kappa of 0.62 (0.55-0.69). Overall, 46 (9.1%) patients were classified as in remission/SACQ by rheumatologists but did not meet the 2021 DORIS criteria for remission. The main reasons for discrepancies were a clinical SLE Disease Activity Index (cSLEDAI) score >0 in 39 patients, a Physician Global Assessment score >0.5 in five patients, and prednisone >5 mg/day in another five patients. CONCLUSIONS: The 2021 DORIS remission is an achievable target in clinical practice. There is substantial agreement between the DORIS definition and physician-judged remission. The discordance was mainly due to physicians classifying some patients with ongoing mild disease activity as in remission. Thus, the standardized DORIS definition should be used to define the target in a treat-to-target strategy for the management of SLE.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Altabás-González I, Rúa-Figueroa Í, Rubiño F, et al. Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement? Rheumatology (Oxford). 2024. PMID: 37039851. doi:10.1093/rheumatology/kead159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。